# A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer

> **NCT05725343** · PHASE3 · TERMINATED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 350 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Canakinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05725343
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-03
- **Primary completion:** 2022-04-03
- **Final completion:** 2022-09-21
- **Target enrollment:** 350 (ACTUAL)
- **Why stopped:** Novartis has decided to terminate the trial due to the recent results made available from the Novartis CANOPY A study (CACZ885T2301), this decision is not related to any safety data for Canakinumab
- **Last updated:** 2023-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05725343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05725343, "A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05725343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*